NEW COMPOUND 2R -(2R*, 3S*, 4R*, 5R*, 8R*, 10R*, 11R*, 12S*, 13S*, 14R*)-13 -(2, 6- DIDEOXY 3-C-METHYI -3 -O-METHYL -A-L-RIBO -HEXOPYRANOSYL) OXY-2-ETHYL-3, 4, 10- TRIHYDROXY -3, 5, 6, 8, 10, 12, 14-HEPTAMETHYL -11-3, 4, 6-TRIDEOXY-3-(DIMETHYLA

摘要

Provided herein is a new compound [2R -(2R*, 3S*, 4R*, 5R*, 8R*, 10R*, 11R*, 12S*, 13S*, 14R*)]-13 -[(2, 6-Dideoxy -3-C-methyI -3 -O-methyl a-L-ribo -hexopyranosyl)oxy] -2-ethyl-3, 4, 10- trihydroxy -3, 5, 6, 8, 10, 12, 14-heptamethyl -11-[[3, 4, 6-trideoxy -3-(dimethylamino) -'-D-xyl -hexopiranosil] oxy]-1-oxa-6 -azacyclopentadecan -15-one or with name of IUPAC 9- deoxo-9a -aza-9a -methyl-9a- homoerythromycin A and which is elucidated, for diverse physicochemical methods, which correspond with the and anhydrous and crystaline form with a tetragonal crystaline system, with spatial group P42212, cell constants a= 14.452 A0, b = 14.452 A0, c = 41.645 A0 and volume 8698 A03. Also herein is depicted the process for obtaining it starting from the amorphous forms, monohydrate, dehydrate, from its salts, from another by-product, from another polymorphous or pseudopolymorphous forms.